MUC-1 CD40L vaccine (MicroVAX)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameMUC-1 CD40L vaccine (MicroVAX)
Drug Alias NameCD40L MUC-1 dendritic cell vaccineMucin antigen vaccine,Ad-sig-hMUC-1/ecdCD40L
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Ovarian EpithelialProstatic Intraepithelial Neoplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMicrovax Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMicrovax LlcSingapore Clinical Research Institute
Active IndicationsN/A
Inactive IndicationsCarcinoma, Ovarian EpithelialProstatic Intraepithelial Neoplasia

Other Information

ATC CodeN/A
Related LinksN/A